This product is delipidated during its purification process from human plasma. Although it is not routinely tested for final lipid contamination, previous lots have been tested by SPIFE Vis Cholesterol Gel against a cholesterol profile standard and no visible lipid contamination had been found.
A0722
Apolipoprotein A-I from human plasma
≥85% (SDS-PAGE), buffered aqueous solution
Synonyme(s) :
Apo A-I
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
| Conditionnement | Référence | Disponibilité | Prix |
|---|---|---|---|
| 0.5 mg | Vérifier la disponibilité des articles du panier | 427.00 CHF | |
| 1 mg | Vérifier la disponibilité des articles du panier | 437.00 CHF |
A propos de cet article
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderbiological source
human plasma
Quality Level
assay
≥85% (SDS-PAGE)
form
buffered aqueous solution
mol wt
28.3 kDa
technique(s)
ELISA: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... APOA1(335)
Application
Apolipoprotein A-I from human plasma has been used to induce cholesterol efflux in nitrobenzoxadiazole (NBD)-cholesterol loaded cells. It has also been used to detect IgG anti-apoA-1 antibodies using enzyme linked immunosorbent assay (ELISA).
Major protein components in high density lipoprotein (HDL)
Biochem/physiol Actions
Activates lecithin-cholesterol acyltransferase (LCAT), which is responsible for cholesterol esterification in plasma.
Apo-AI comprises ~70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 245 amino acids with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular mass is reported to be 28.3 kDa. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-AI shows a high content of α-helix structure. The amphipathic regions in the α-helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-AI shows self-association with minor conformation change. Apo-AI activates lecithin-cholesterol (LCAT) acyltransferase, which is responsible for cholesterol esterification in plasma.
Apo-AI levels in normal plasma are 90-130 mg/dl. Apo-AI levels may be inversely related to the risk of coronary disease.
Apo-AI levels in normal plasma are 90-130 mg/dl. Apo-AI levels may be inversely related to the risk of coronary disease.
Physical form
Solution in 10 mM ammonium bicarbonate
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
1 of 1
Cet article | |||
|---|---|---|---|
| biological source human plasma | biological source human plasma | biological source human plasma | biological source - |
| technique(s) ELISA: suitable | technique(s) - | technique(s) electrophoresis: suitable | technique(s) - |
| assay ≥85% (SDS-PAGE) | assay ≥95% (SDS-PAGE) | assay ≥95% (SDS-GE) | assay ≥95% (SDS-PAGE) |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
| form buffered aqueous solution | form buffered aqueous solution | form buffered aqueous solution | form liquid |
| shipped in dry ice | shipped in dry ice | shipped in - | shipped in wet ice |
Classe de stockage
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Articles
Lipoproteins package cholesterol for transport in plasma, essential for lipid transport and cellular function in the body.
Contenu apparenté
Anti-ApoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals
Lagerstedt JO, et al.
Journal of Internal Medicine, 285(1), 49-58 (2019)
Gantsetseg Tumurkhuu et al.
Cell metabolism, 28(3), 432-448 (2018-06-26)
Pathogen burden accelerates atherosclerosis, but the mechanisms remain unresolved. Activation of the NLRP3 inflammasome is linked to atherogenesis. Here we investigated whether Chlamydia pneumoniae (C.pn) infection engages NLRP3 in promoting atherosclerosis. C.pn potentiated hyperlipidemia-induced inflammasome activity in cultured macrophages and
Sara Croca et al.
Arthritis research & therapy, 17, 26-26 (2015-04-19)
IgG anti-apolipoprotein A-1 (IgG anti-apoA-1) antibodies are present in patients with systemic lupus erythematosus (SLE) and may link inflammatory disease activity and the increased risk of developing atherosclerosis and cardiovascular disease (CVD) in these patients. We carried out a rigorous
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| A0722-.5MG | 04061833334317 |
| A0722-1MG | 04061833334324 |
-
Is Product No. A0722, ApoA1 delipidated?
1 answer-
Helpful?
-